Deutsche Bank raised the firm’s price target on CVS Health (CVS) to $70 from $66 and keeps a Buy rating on the shares. The company issued a ...

In a report released yesterday, Elizabeth Anderson CFA from Evercore ISI maintained a Buy rating on CVS Health (CVS – Research Report), with a ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

(Reuters) - CVS Health beat Wall Street estimates for fourth-quarter profit on Wednesday and provided an annual forecast that ...